JNJ
Johnson & Johnson
NYSE · usd
Johnson & Johnson (JNJ) trades at $263.81 (-1.42%) as of 7:59:31 PM EDT on Oct 23, 2026, -2.54% over the past month. Market cap is $644.22B, with 3.3 days to cover in short interest.
Stock performance
How Johnson & Johnson (JNJ) stock has performed from one day to one year, with its 52-week range.
- 1D
- -1.42%
- 1W
- +3.23%
- 1M
- -2.54%
- YTD
- +27.48%
- 1Y
- +38.63%
- 52-wk range
- $184.66 – $281.07
Key statistics
Today's trading snapshot for JNJ: day range, open, previous close, volume and market cap.
- Day range
- $262.40 – $266.03
- Open
- $265.82
- Prev close
- $267.61
- Volume
- 5.31M
- Market cap
- $644.22B
- Shares out
- 2.41B
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Johnson & Johnson: P/E, P/S, P/B, ROE and more.
- P/E
- 40.03
- P/S
- 6.49
- P/B
- 7.90
- P/FCF
- 31.88
- ROE
- 19.7%
- ROA
- 8.2%
- Debt/Equity
- 0.55
- Div yield
- 1.97%
As of Oct 22, 2026
8-K filings
Material corporate events Johnson & Johnson has disclosed to the SEC on Form 8-K.
- Earnings and performanceOct 13, 2026
On October 13, 2026, Johnson & Johnson (the "Company") issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended September 27, 2026.
- Executive leadershipAug 4, 2026
Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee effective September 1, 2026.
- Guidance and outlookJul 29, 2026
As a result of these transactions, the Company is updating its full year 2026 guidance relative to the guidance previously issued on July 15, 2026" with updated Adjusted operational sales, Operational sales, Adjusted pre-tax operating margin, Adjusted operational EPS, and Adjusted EPS figures.
- Material agreementsJul 28, 2026
The Company announced that it has reached an agreement for a comprehensive resolution of the ovarian talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned upon, among other things, the express participation of at least of 95% of the remaining claims. The agreement calls for per claim payments, with a $5.5 billion commitment by the Company, and the first payment of no more than $3 billion to be made in 2027 and no additional payments due before 2028.
- Earnings and performanceJul 15, 2026
Johnson & Johnson (the "Company") issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the second quarter ended June 28, 2026.
Dividend history and stock splits
Johnson & Johnson's recent dividend payments and stock splits.
Dividends
- $1.34ex-div Nov 24, 2026
- $1.34ex-div Aug 25, 2026
- $1.34ex-div May 26, 2026
- $1.30ex-div Feb 24, 2026
Splits
No recent splits.
JNJ short interest
How heavily JNJ is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 3.3
- Short interest
- 22.07M
- Avg volume
- 6.75M
As of · reported to FINRA twice monthly.
JNJ news
The latest news and headlines about Johnson & Johnson (JNJ).
- CHMP empfiehlt die Zulassung von Johnson & Johnsons TALVEY®▼ (Talquetamab) plus Daratumumab zur Behandlung des rezidivierten/refraktären multiplen Myeloms in einer früheren TherapieliniepositiveGlobeNewswire Inc.· Oct 23, 2026
- Le CHMP recommande l’approbation de TALVEY®▼ (talquetamab) de Johnson & Johnson, en association avec le daratumumab, dans une ligne de traitement plus précoce du myélome multiple en rechute/réfractairepositiveGlobeNewswire Inc.· Oct 23, 2026
- Il CHMP raccomanda l'approvazione di TALVEY®▼ (talquetamab) di Johnson & Johnson in combinazione con daratumumab nel trattamento in una linea terapeutica più precoce del mieloma multiplo recidivante/refrattariopositiveGlobeNewswire Inc.· Oct 23, 2026
- Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsightpositiveGlobeNewswire Inc.· Oct 22, 2026
- Vanguard Health Care ETF vs iShares U.S. Healthcare ETFpositiveThe Motley Fool· Oct 21, 2026
Frequently asked questions
What is the Johnson & Johnson (JNJ) stock price today?
Johnson & Johnson (JNJ) is trading at $263.81 (-1.42% on the day) as of 7:59:31 PM EDT on Oct 23, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Johnson & Johnson?
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023.
What is the short interest in JNJ?
As of Sep 30, 2026, JNJ has 22.07M shares short and 3.3 days to cover.
Does Johnson & Johnson (JNJ) pay a dividend?
Yes. Johnson & Johnson (JNJ)'s most recent dividend was $1.34 per share, with an ex-dividend date of Nov 24, 2026. Full JNJ dividend history is available from the Massive API.
What exchange is JNJ listed on?
Johnson & Johnson (JNJ) trades on NYSE in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of JNJ with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a JNJ analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.